A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Jianzhong Zhang, Jinyan Wang et al.|British Journal of Dermatology|2024Cited by 21
Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trialKun Huang, Min Zheng, Songmei Geng et al.|Chinese Medical Journal|2025Cited by 0